Science brief
In Memoriam: Ada Yonath and $5.3M for Israeli Cancer Labs
Israel mourns its first female Nobel laureate while fresh philanthropic grants bolster university oncology research across the country.
Science
Ada Yonath's mapping of the ribosome gave medicine its blueprint for modern antibiotics — anchoring Israel's foundational role in global structural biology.
BackgroundProf. Yonath received the 2009 Nobel Prize in Chemistry for mapping the cellular machine that synthesizes proteins. She built Israel's first protein crystallography lab at the Weizmann Institute, pushing through decades of skepticism from international peers.
- Yonath mapped how cellular ribosomes decode genetic instructions, providing the structural basis for understanding protein synthesis in living organisms.
- Her detailed atomic models revealed exactly where therapeutic antibiotics bind to bacterial ribosomes, directly guiding modern pharmaceutical development.
- She spent more than 50 years leading research teams at the Weizmann Institute and Hebrew University, mentoring generations of Israeli scientists.
Science
Sustained philanthropic capital from ICRF protects early-stage Israeli lab research — ensuring pipeline continuity for next-generation oncology breakthroughs.
BackgroundThe Israel Cancer Research Fund is the largest non-governmental source of biomedical cancer research funding in Israel. Since 1975, the charity has distributed nearly $109 million across more than 3,000 grant projects.
- Grants support leading laboratories across the Weizmann Institute, Hebrew University, Technion, and Tel Aviv University, maintaining core research capacity.
- Targeted research tracks focus on personalized cancer immunotherapies and machine-learning models designed for early tumor detection.
- The predictable grant cycle offers vital bridge capital for early-stage investigators before they seek larger commercial or international funding.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
